Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70

Chinese Medical Journal

Volumn 122, Issue 21, 2009, Pages 2540-2546

  Li, Yan ^a   Li, Qiang ^b   Li, Cheng Jiang ^c   Wang, Chang Jiang ^d   Zheng, Yi Man ^e   Issa, Maher ^f   Zhang, Jia ^e  

^a SUN YAT SEN UNIVERSITY   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d ANHUI MEDICAL UNIVERSITY   (China)

^e Eli Lilly China ^*  (China)

^f ELI LILLY AND COMPANY   (United States)

Author keywords

Chinese patient; Diabetes mellitus; Hemoglobin A1c protein, human; Insulin

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN LISPRO;

ADULT; AGED; ARTICLE; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DIARRHEA; DIET RESTRICTION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; EVENING DOSAGE; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; HYPOGLYCEMIC COMA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PHASE 4 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 73449130201     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2009.21.004     Document Type: Article

References (20)

1. Gu D, Reynolds K, Duan X, Xin X, Chen J, Wu X, et al. Prevalence of diabetes and impaired fasting glucose in the Chinese adult population: International Collaborative Study of Cardiovascular Disease in Asia (InterASIA). Diabetologia 2003; 46: 1190-1198.
2. Chan J, Ng MC, Critchley JA, Lee SC, Cockram C. Diabetes mellitus - a special medical challenge from a Chinese perspective. Diabetes Res Clin Pract 2001; 54 Suppl 1: s19-s27.
3. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
4. Epidemiology of Diabetes Interventions and Complications Trial Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643-2653.
5. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405-412.
6. Hirsch IB, Bergenstal RM, Parkin CG, Wright E Jr., Buse JB. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005; 23: 78-86.
7. Wright E Jr., Scism-Bacon JL, Glass LC. Oxidative stress in type 2 diabetes: the role of fasting and postprandial glycaemia. Int J Clin Pract 2006; 60: 308-314.
8. Garber AJ, Lighthelm R, Christiansen JS, Liebl A. Premixed insulin treatment for type 2 diabetes: analogue or human? Diabetes Obes Metab 2007; 9: 630-639.
9. Roach P, Woodworth JR. Clinical pharmacokinetics and pharmacodynamics of insulin lispro mixtures. Clin Pharmacokinet 2002; 41: 1043-1057.
10. Howey DC, Bowsher R, Brunelle RL, Woodworth J. [Lys(B28)Pro(B29)]-human insulin: a rapidly absorbed analogue of human insulin. Diabetes 1994; 43: 396-402.
11. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999; 22: 459-462.
12. Ning G, Xiang K, Gao Y, Bi Y, Wu S, Guo X, et al. Comparison of post-prandial blood glucose excursions between insulin lispro 75/25 and human insulin 70/30 in Chinese patients with type 1 or type 2 diabetes. J World Med 2005; 9: 14-22.
13. International Diabetes Federation-West Pacific Region [IDF-WPR]. Type 2 diabetes: practical targets and treatments. 3rd ed. Sydney (Australia): Health Communications Australia Pty Limited and In vivo Communications Pty Limited; 2002: 25.
14. Grizzle JE. The two-period change-over design and its use in clinical trials. Biometrics 1965; 21: 467-480.
15. Kenward MG, Roger JH. Small sample inference for fixed effects from restricted maximum likelihood. Biometrics 1997; 53: 983-997.
16. Roach P, Yue L, Arora V. The Humalog MIX25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999; 22: 1258-1261.
17. Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, et al. Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus. Clin Ther 2000; 22: 222-230.
18. Executive summary: standards of medical care in diabetes - 2009. Diabetes Care 2009; 32 Suppl 1: s6-s12.
19. Sun P, Wang R, Jacober S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. Curr Med Res Opin 2007; 23: 3017-3023.
20. Holman R, Paul S, Bethel A, Matthews D, Neil H. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577-1589.